corticosteroids

Seven Biologics, Up to $47,000 a Year, and 89 Percent of Europe's Severe Asthmatics Still Aren't in Remission

The Lancet calls severe asthma an 'unmet need.' A 13,455-patient European registry shows most of those patients are already on the pricey biologics, and 89 percent still have active disease.